MX2022007844A - Tratamiento de una lesion cerebral traumatica moderada. - Google Patents
Tratamiento de una lesion cerebral traumatica moderada.Info
- Publication number
- MX2022007844A MX2022007844A MX2022007844A MX2022007844A MX2022007844A MX 2022007844 A MX2022007844 A MX 2022007844A MX 2022007844 A MX2022007844 A MX 2022007844A MX 2022007844 A MX2022007844 A MX 2022007844A MX 2022007844 A MX2022007844 A MX 2022007844A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- brain injury
- traumatic brain
- mild traumatic
- mtbi
- Prior art date
Links
- 208000007333 Brain Concussion Diseases 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 230000002459 sustained effect Effects 0.000 abstract 2
- 102000012004 Ghrelin Human genes 0.000 abstract 1
- 101800001586 Ghrelin Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962953130P | 2019-12-23 | 2019-12-23 | |
| PCT/US2020/066703 WO2021133844A1 (en) | 2019-12-23 | 2020-12-22 | Treatment of mild traumatic brain injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007844A true MX2022007844A (es) | 2022-09-07 |
Family
ID=76575665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007844A MX2022007844A (es) | 2019-12-23 | 2020-12-22 | Tratamiento de una lesion cerebral traumatica moderada. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230031262A1 (https=) |
| EP (1) | EP4081238A4 (https=) |
| JP (1) | JP2023508250A (https=) |
| KR (1) | KR20220122691A (https=) |
| CN (1) | CN114980915A (https=) |
| AU (1) | AU2020412765A1 (https=) |
| BR (1) | BR112022012365A2 (https=) |
| CA (1) | CA3165738A1 (https=) |
| IL (1) | IL294156A (https=) |
| MX (1) | MX2022007844A (https=) |
| WO (1) | WO2021133844A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220370804A1 (en) * | 2021-01-22 | 2022-11-24 | The Regents Of The University Of Colorado, A Body Corporate | Motor learning and vagus nerve stimulation (vns) paired with motor learning to treat demyelinating diseases, conditions and disorders |
| CN113723530B (zh) * | 2021-09-02 | 2022-03-25 | 中国科学院自动化研究所 | 基于视频分析和电子心理沙盘的智能心理评估系统 |
| AU2023338304A1 (en) * | 2022-09-07 | 2025-04-10 | Oxeia Biopharmaceuticals, Inc. | Treatment of mild traumatic brain injury |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6545697B2 (ja) * | 2013-11-15 | 2019-07-17 | ニューラル・アナリティクス・インコーポレーテッド | 神経学的状態の診断のための脳の血流速度の構造的特徴をモニタリングすること |
| US9119832B2 (en) * | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| WO2015168103A1 (en) * | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| AU2015305647A1 (en) * | 2014-08-19 | 2017-04-06 | Oxeia Biopharmaceuticals, Inc. | Methods of treating mild brain injury |
| WO2016134215A1 (en) * | 2015-02-19 | 2016-08-25 | The Regents Of The University Of California | Methods of treating mild brain injury and post-traumatic stress disorder |
| US20180071367A1 (en) * | 2015-03-09 | 2018-03-15 | Oxeia Biopharmaceuticals, Inc. | Methods of treating cognitive impairments or dysfunction |
| WO2017075535A1 (en) * | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
-
2020
- 2020-12-22 BR BR112022012365A patent/BR112022012365A2/pt not_active Application Discontinuation
- 2020-12-22 WO PCT/US2020/066703 patent/WO2021133844A1/en not_active Ceased
- 2020-12-22 EP EP20905518.5A patent/EP4081238A4/en active Pending
- 2020-12-22 AU AU2020412765A patent/AU2020412765A1/en active Pending
- 2020-12-22 KR KR1020227025653A patent/KR20220122691A/ko not_active Withdrawn
- 2020-12-22 CA CA3165738A patent/CA3165738A1/en active Pending
- 2020-12-22 IL IL294156A patent/IL294156A/en unknown
- 2020-12-22 JP JP2022564096A patent/JP2023508250A/ja active Pending
- 2020-12-22 CN CN202080092650.7A patent/CN114980915A/zh active Pending
- 2020-12-22 US US17/787,848 patent/US20230031262A1/en active Pending
- 2020-12-22 MX MX2022007844A patent/MX2022007844A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022012365A2 (pt) | 2022-08-30 |
| CN114980915A (zh) | 2022-08-30 |
| CA3165738A1 (en) | 2021-07-01 |
| JP2023508250A (ja) | 2023-03-01 |
| US20230031262A1 (en) | 2023-02-02 |
| AU2020412765A1 (en) | 2022-07-14 |
| WO2021133844A1 (en) | 2021-07-01 |
| EP4081238A4 (en) | 2023-08-30 |
| EP4081238A1 (en) | 2022-11-02 |
| IL294156A (en) | 2022-08-01 |
| KR20220122691A (ko) | 2022-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007844A (es) | Tratamiento de una lesion cerebral traumatica moderada. | |
| PH12021550882A1 (en) | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | |
| WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| PH12021550047A1 (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| JOP20200041B1 (ar) | تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي | |
| SG11202107325TA (en) | Methods and compositions for the treatment of fabry disease | |
| EP4252842A3 (en) | Ecm hydrogel for treating esophageal inflammation | |
| MX2024008461A (es) | Metodos para tratar trastornos linfoproliferativos malignos. | |
| MX2009012188A (es) | Métodos de tratamiento y prevención de enfermedades y desórdenes neurodegenerativos. | |
| JOP20210324A1 (ar) | مشتقات من 2h-indazole واستخدامها في علاج مرض | |
| MX2021014905A (es) | Células seguras e invisibles para el sistema inmunitario. | |
| EP3590338A3 (en) | Medical treatments based on anamorelin | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| WO2019157527A3 (en) | Methods related to parkinson's disease and synucleinopathies | |
| CL2020002465A1 (es) | Método de tratamiento de enfermedad fibrótica | |
| EA201891007A1 (ru) | Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца | |
| MX2019009586A (es) | Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal. | |
| MX2018007152A (es) | Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de la disfuncion del esfinter gastrointestinal. | |
| PH12021552741A1 (en) | Solid forms of a glyt1 inhibitor | |
| WO2008157747A8 (en) | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders | |
| MX2020003243A (es) | Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. | |
| GB202011522D0 (en) | Neuromodulation for the treatment of circulatory system diseases | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы |